Skip to main content
Beta Version — Features and pricing may change. Send feedback
CadNews - Comparative News Analysis
Sign in
Back to brief

Politics · October 8, 2026

FDA: Mifepristone review won't be done until March

Confidence 5%
Spin 3%
2 sources analyzed →

CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.

Neutral Summary

The Food and Drug Administration (FDA) has announced in a court filing that it expects to complete a new safety review of the abortion pill mifepristone by March. This review, initiated under the Trump administration following pressure from conservative groups and lawmakers, will compare the safety of the medication to surgical abortions through 10 weeks of gestation using data from approximately 100,000 patients. The agency is currently re-evaluating its previous decision to allow the drug to be dispensed via telehealth, a provision currently being challenged in a Louisiana federal court.

The Food and Drug Administration (FDA) has announced in a court filing that it expects to complete a new safety review of the abortion pill mifepristone by March. This review, initiated under the Trump administration following pressure from conservative groups and lawmakers, will compare the safety of the medication to surgical abortions through 10 weeks of gestation using data from approximately 100,000 patients. The agency is currently re-evaluating its previous decision to allow the drug to be dispensed via telehealth, a provision currently being challenged in a Louisiana federal court.